September 2023 in “Journal of The American Academy of Dermatology” Dutasteride is safe and effective long-term for male hair loss.
November 2013 in “Journal of clinical & experimental dermatology research” Dutasteride can help treat hair loss in both men and women.
January 2014 in “Anales Médicos de la Asociación Médica del Centro Médico ABC” The combination of oral finasteride and dutasteride with topical minoxidil effectively promotes new hair growth in most people, with minimal side effects.
February 2025 in “Journal of the European Academy of Dermatology and Venereology” Oral dutasteride is a recommended first treatment for frontal fibrosing alopecia.
March 2002 in “Hair transplant forum international” Dutasteride's effect on hair loss treatment is uncertain and should be used cautiously.
February 2021 in “Reactions Weekly” Finasteride and dutasteride may cause macular abnormalities.
May 2025 in “Journal of the European Academy of Dermatology and Venereology”
April 2018 in “Expert Opinion on Drug Safety” Dutasteride is a safe and effective treatment for hair loss.
2 citations
,
April 2016 in “Journal of The American Academy of Dermatology” Dutasteride more effective than finasteride for hair growth; SM04554 safe and potentially effective for hair loss.
November 2024 in “Nanomaterials” The nanocrystalline suspension effectively delivers dutasteride over time with minimal inflammation.
7 citations
,
May 2008 in “PubMed” Dutasteride is more effective than finasteride in reducing urinary retention and surgery risks in people aged 65 and older.
December 2010 in “Actas Urológicas Españolas” Taking dutasteride for one month before prostate surgery can reduce bleeding.
4 citations
,
September 2006 in “European Urology Supplements” Dutasteride reduces DHT and improves BPH symptoms more effectively than finasteride.
Finasteride and dutasteride might lower melanoma risk.
May 2023 in “Elsevier eBooks” Minoxidil, finasteride, and dutasteride are treatments for hair loss.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Dutasteride 0.5 mg/day is the best treatment for male pattern baldness.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Dutasteride 0.5 mg/day is the best treatment for male pattern baldness.
6 citations
,
October 2021 in “Brain Sciences” Dutasteride may help reduce brain inflammation and improve cognition.
February 2026 in “European Urology”
Dutasteride can stabilize hair loss in patients with frontal fibrosing alopecia, but its safety in women is unclear, so use it with caution.
September 2015 in “Korean Journal of Clinical Pharmacy” Dutasteride is highly effective for hair loss treatment in Korea, with more side effects than finasteride.
1 citations
,
January 2015 in “Hair therapy & transplantation” New drug dutasteride effectively treats hair loss, but use cautiously due to potential sexual side effects.
January 2007 in “Inpharma Weekly” Dutasteride is more effective for male pattern baldness than finasteride, and black cohosh extract BNO 1055 is as effective as conjugated estrogens in treating postmenopausal symptoms, with added benefits in reducing sweating and mental symptoms.
13 citations
,
November 2016 in “The Journal of urology/The journal of urology” Dutasteride is as safe for the heart as finasteride.
October 2024 in “Actas Dermo-Sifiliográficas” Finasteride and dutasteride can increase beard thickness in men.
November 2025 in “JAAD Case Reports” Oral dutasteride, minoxidil, and finasteride may help reduce hair loss in breast cancer survivors, but more research is needed.
195 citations
,
February 2007 in “The Journal of Clinical Endocrinology and Metabolism” Dutasteride and finasteride may reduce sperm count and volume but don't affect movement or shape; effects are reversible after stopping.
2 citations
,
February 2007 in “PubMed” Dutasteride is cheaper than finasteride for treating benign prostatic hyperplasia.
January 2026 in “Reactions Weekly” Both finasteride and dutasteride can cause sexual side effects, but they may differ in frequency and severity.
March 2005 in “The Nurse Practitioner”